It is almost cliché now to mention that the COVID-19 pandemic was the proving ground for Decentralized Clinical Trials (DCTs) – the perfect catalyst to accelerate their development and adoption. With site and participant experience backing the benefit of DCTs, there is an understandable push by sponsors to scale remote research among their portfolio of clinical trials. To keep up, many sponsors are considering building their own, purchasing, or licensing DCT technology.
Europe, Middle East & Africa
Risks to Sponsors Developing and Running Their Own DCT Technology
Jun 22, 2022
Related Solutions
Site and Investigators
Helping Sites and Investigators grow through innovation and collaboration
Decentralized Trials
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
Patient Engagement Suite
Technology informed by unparalleled Decentralized Trials (DCT) operational experience and delivered at global scale.